PLXNA3 and cancer: In terms of sex hormone levels, the testosterone levels in the cancer group (377.35 ± 204.26 ng/dL) were significantly lower than that in the non-cancer group (415.02 ± 183.92 ng/dL)(P < 0.001), reflecting the possibility of androgen deficiency in cancer patients.